NT-proANP and NT-proBNP circulating levels as predictors of cardiovascular outcome following coronary stent implantation

•The predictive role of both NT-proANP and NT-proBNP circulating levels toward cardiovascular outcome was assessed in a cohort of both stable and unstable CAD patients undergoing PCI in a non-primary PCI setting.•Following PCI, higher levels of both NT-proNPs were associated to higher occurrence of MACEs [composite of cardiac death, non-fatal myocardial infarction and clinically driven target lesion revascularization (c-TLR)] at follow up.•Notably, NT-proANP levels were an independent predictor of MACEs by Cox regression analysis. Kaplan-Meyer curves revealed that patients with elevated NT-proANP levels (> 2.100 fmol/mL) had a lower MACE free survival (p = 0.003).•Our findings support the key role of natriuretic peptides in ischemic heart disease.

BackgroundNatriuretic peptides are diagnostic/prognostic biomarkers in major cardiovascular diseases. We aimed at assessing the predictive role of N-terminal pro-A-type (NT-proANP) and pro-B-type (NT-proBNP) natriuretic peptides levels toward cardiovascular outcome in both stable and unstable coronary artery disease (CAD) patients after percutaneous coronary intervention (PCI) in a non-primary PCI setting.MethodsA total of 395 patients undergoing PCI with stent implantation for either stable angina (SA) or non ST-elevation acute coronary syndrome (NSTE-ACS) were enrolled. Pre-procedural NT-proANP and NT-proBNP levels were measured. Occurrence of major adverse cardiac events (MACEs), composite of cardiac death, non-fatal myocardial infarction, and clinically driven target lesion revascularization (c-TLR), was the endpoint of the study. Follow up mean time was 48.53 ± 14.69 months.ResultsMACEs occurred in forty-four patients (11%) during follow up. Both NT-proANP levels [3170 (2210-4630) vs 2283 (1314-3913) fmol/mL, p = 0.004] and NT-proBNP levels [729 (356-1353) vs 511 (267-1006) fmol/mL, p = 0.04] were significantly higher in patients with MACEs compared to patients without MACEs. Similar results were found when considering hard MACEs (myocardial infarction and cardiac death). NT-proANP levels were significantly higher in patients with c-TLR compared with patients without c-TLR [3705 (2766-5184) vs 2343 (1340-3960) fmol/mL, p = 0.021]. At multivariate analysis, NT-proANP levels were a significant predictor of MACEs (HR 1.09, 95% CI 1.03-1.18, p = 0.04). Kaplan-Meyer curves revealed that patients with elevated NT-proANP levels (> 2.100 fmol/mL) had a lower MACE free survival (p = 0.003).ConclusionsBoth NT-proANP and NT-proBNP levels were higher in CAD patients experiencing MACEs following PCI in a non-primary setting. Notably, only NT-proANP levels significantly affected prognosis after PCI.